https://www.siliconvalley.com/2020/10/23/coronavirus-bay-area-based-gilead-earns-fda-approval-for-covid-19-treatment/

A Bay Area drugmaker became the first to earn approval from the Food and Drug Administration for a therapeutic to help treat serious cases of COVID-19, the company and agency announced Thursday.

Remdesivir, which was developed by Gilead Science in Foster City, was shown to reduce recovery time in hospitalized patients through a trio of Phase 3 trials, including one double-blind, randomized study by the National Institute of Allergy and Infectious Diseases. The FDA approved its use for any patient 12 years or older and weighing at least 88 pounds who is hospitalized with COVID-19.